Obinutuzumab [949142-50-1]
Cat# HY-P9910-1mg
Size : 1mg
Brand : MedChemExpress
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
For research use only. We do not sell to patients.
CAS No. : 949142-50-1
This product is a controlled substance and not for sale in your territory.
Based on 1 publication(s) in Google Scholar
Description |
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma. |
---|---|
Isotype |
Human IgG1 kappa |
Recommend Isotype Controls |
Human IgG1 kappa, Isotype Control |
Species |
Humanized |
In Vitro |
Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab[1] MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
In Vivo |
Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed[2]. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab[1]. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
Clinical Trial |
|
CAS No. |
949142-50-1 |
Appearance |
Liquid |
Color |
Colorless to light yellow |
SMILES |
[Obinutuzumab] |
Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
Format |
|
Biological Activity |
|
Purity & Documentation |
Purity: 99.40% |
References |
|
Obinutuzumab Related Classifications
- Cancer
- Cancer Targeted Therapy Cancer Immunotherapy
- Inhibitory Antibodies
- Immunology/Inflammation
- CD20
Molarity Calculator
Dilution Calculator
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Obinutuzumab949142-50-1GA101 Anti-Human CD20 type II, Humanized AntibodyGA 101GA-101CD20Inhibitorinhibitorinhibit